Pharma

Researchers from Washington University School of Medicine are now conducting a clinical trial of antidepressant drug fluvoxamine, as a potential treatment for the ‘cytokine storm’...

In 2019 the US Food and Drug Administration (FDA) accepted 119 New Drug Approvals (NDAs) and Biologics License Applications (BLAs) including New Molecular Entities (NMEs)...

As the COVID-19 global pandemic grows with the UK, active inflammatory bowel disease (IBD) patients could be at a higher risk, as patients using prominent therapies...

The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) declined by 28% during the week ended April 12, 2020 compared to the previous week, according to GlobalData’s deals database. Aurojyoti Bose, Analyst at GlobalData, comments: “The decline was subsequent to two...

Novo Nordisk will continue to dominate a large share of the glucagon-like peptide-1 receptor agonist (GLP-1RA) market with the arrival of Rybelsus and Ozempic’s strong global sales of $1.65bn in 2019. This will enable the company to maintain its well-established position in the wider diabetes market, according to GlobalData, a leading data and analytics company. Akash Patel...

As COVID-19 spreads, the search for a treatment is ramping up. The antimalarial and immunosuppressant hydroxychloroquine has received some attention, including that of President Trump. There are currently around 60 planned...

Despite the plethora of drugs currently available for patients with psoriatic arthritis (PsA), several key unmet needs remain, according to GlobalData, a leading data and analytics company.The company’s report: ‘Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028’ reveals...

The bladder cancer market is expected to significantly grow from $733m in 2018 to $4.0bn by 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 18.5%, according to GlobalData, a leading data and...

In the event of a free trade agreement with the EU, the UK will continue to be bound by current EU laws, thereby adhering to the new Medical Device Regulation (MDR). This will significantly change the landscape of the medical device industry, says GlobalData, a leading data...

Following the recent news that Roche’s Phase III influenza drug Xofluza met its primary endpoint for influenza prevention, Philipp Rosenbaum, Pharma Analyst at GlobalData, a leading...

Pills on a white background

Multiple big pharma companies are developing new anti-obesity drugs, including Novo Nordisk, Sanofi, and AstraZeneca and six drugs are expected to launch by 2026, according...

pills medicine healthcare

Takeda’s possible $65B takeover of Shire could be the largest deal value in pharma this year, says GlobalData a leading data and analytics company. This...

NASH webinar- Understand the NASH Market Landscape

Affecting more than 60 million people worldwide, and with no approved therapies, nonalcoholic steatohepatitis (NASH) presents a wealth of opportunities for drug developers. Join GlobalData's...

Slow growth in pharmaceutical sales over recent years has spurred considerable interest and investment into emerging global markets: Brazil, Russia, India, China and South Korea...